Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Radiol Case Rep ; 16(4): 899-902, 2021 Apr.
Article in English | MEDLINE | ID: covidwho-1065545


Subacute mesenteric venous thrombosis is vascular complication commonly associated with hypercoagulability, resulting in abdominal pain and ischemia of intestines. We report a 44-year-oldo male without relevant history and COVID-19 disease who developed abdominal pain after onset of respiratory symptoms. Imaging studies demonstrated abnormal findings on Doppler ultrasoud and computed tomography scan compatible with thrombotic disease, successfully treated with anticoagulation therapy. This case exemplifies the heterogeneous presentation of late thrombotic complications in COVID-19 and the relevance of prophylactic measures against hypercoagulability.

Am J Case Rep ; 22: e927011, 2021 Jan 01.
Article in English | MEDLINE | ID: covidwho-1005105


BACKGROUND Pandemic coronavirus disease 2019 (COVID-19) originated in Wuhan, China, and is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Severe respiratory symptoms are a hallmark of the disease, which may also include complications related to a hypercoagulable state and central nervous system involvement. These complications can occur during either the acute or the recovery phase. The cerebral involvement typically manifests as intracranial hypertension, intracerebral hemorrhage, diffuse encephalopathy, or cerebral venous thrombosis. The hemorrhagic form of cerebral venous thrombosis can be a diagnostic challenge and is treated by anticoagulation therapy, despite the existence of an intracerebral hemorrhage. This report describes a case of superficial cerebral venous thrombosis and intracerebral hematoma in a 48-year-old man weeks after recovering from the acute phase of SARSCoV-2 infection. CASE REPORT A 48-year-old man with a past medical history of SARS-CoV-2 infection confirmed by SARS-CoV-2 reverse-transcription polymerase chain reaction presented with left upper-limb numbness, weakness, and impaired positional sensorium. After initial stabilization, noncontrast computerized tomography and magnetic resonance imaging confirmed an intracerebral hemorrhage with underlying cerebral venous thrombosis. The patient was successfully treated with enoxaparin anticoagulation therapy, and symptoms improved over the following 12 days. CONCLUSIONS Central nervous system venous thrombosis is an atypical presentation of the hypercoagulable state primarily seen in younger patients, and it can occur in a delayed fashion after recovery from mild forms of COVID-19.

COVID-19/complications , Cerebral Hemorrhage/diagnostic imaging , Hematoma/diagnostic imaging , Intracranial Thrombosis/diagnostic imaging , Venous Thrombosis/diagnostic imaging , Anticoagulants/therapeutic use , Cerebral Hemorrhage/virology , Enoxaparin/therapeutic use , Hematoma/virology , Humans , Intracranial Thrombosis/drug therapy , Intracranial Thrombosis/virology , Magnetic Resonance Imaging , Male , Middle Aged , Tomography, X-Ray Computed , Venous Thrombosis/drug therapy , Venous Thrombosis/virology
Front Pharmacol ; 11: 1124, 2020.
Article in English | MEDLINE | ID: covidwho-732859


BACKGROUND: Heparin administration in COVID-19 patients is recommended by expert consensus, although evidence about dosage, duration and efficacy are limited. We aim to investigate the association between different dosages of low molecular weight heparin (LMWH) and mortality among COVID-19 hospitalized patients. METHODS AND RESULTS: Retrospective study of 450 laboratory-confirmed COVID-19 patients admitted to Sant'Orsola Bologna Hospital from March 01 to April 10, 2020. Clinical, laboratory and treatment data were collected and analyzed. The in-hospital mortality between COVID-19 patients treated with standard prophylactic LMWH dosage vs. intermediate LMWH dosage was compared. Out of 450 patients, 361 received standard deep vein thrombosis (DVT) prophylaxis enoxaparin treatment (40-60mg daily) and 89 patients received intermediate enoxaparin dosage (40-60 mg twice daily) for 7 days. No significant differences in the main demographic characteristics and laboratory testings at admission were observed in the two heparin regimen subgroups, except for older age and prevalence of hypertension in the group treated with "standard" prophylaxis LMWH dosage. The intermediate LMWH administration was associated with a lower in-hospital all-cause mortality compared to the "standard" prophylactic LMWH dosage (18.8% vs. 5.8%, p = 0.02). This difference remained significant after adjustment with the propensity score for variables that differed significantly between the dosage groups (OR= 0.260, 95% CI 0.089-0.758, p=0.014). CONCLUSIONS: Intermediate LMWH dosage seems to be associated with lower incidence of mortality compared to standard DVT prophylaxys in hospitalized COVID-19 patients. Our study paves the way to further pathophysiological investigations and controlled studies of anticoagulation therapy in Covid-19 disease.